argenx (ARGX) Stock Overview
A commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
ARGX Community Fair Values
Create NarrativeSee what 75 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
€686.43
FV
20.2% overvalued intrinsic discount15.00%
Revenue growth p.a.
47
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
argenx SE Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €825.20 |
| 52 Week High | €818.40 |
| 52 Week Low | €456.60 |
| Beta | -0.033 |
| 1 Month Change | 18.90% |
| 3 Month Change | 27.50% |
| 1 Year Change | 79.24% |
| 3 Year Change | 134.57% |
| 5 Year Change | 217.75% |
| Change since IPO | 10,345.57% |
Recent News & Updates
Narrative Update • Jun 30
ARGX: Myositis Phase 3 Readouts Will Shape Future Earnings Power
Analysts have nudged their average price targets for argenx higher, citing a series of recent target increases into the €1,059 to about €1,291 range and arguing that the market may still underappreciate the potential of Vyvgart in autoimmune myositis and related indications. Analyst Commentary Recent research on argenx centers on how Vyvgart and the broader myositis program could influence the company’s long term value, with several firms updating their models ahead of key Phase 3 readouts.
Narrative Update • Jun 16
ARGX: Phase 3 Myositis And ALKIVIA Outcomes Will Test Elevated Stock Expectations
The analyst fair value estimate for argenx has been revised from €614.80 to €644.90 as analysts factor in higher Street price targets and upcoming Phase 3 myositis and ALKIVIA study readouts for Vyvgart and efgartigimod. Analyst Commentary on argenx Recent Street research around argenx highlights a mix of optimism on the clinical pipeline and caution on execution and valuation, giving investors a more balanced picture of risk around Vyvgart and efgartigimod ahead of the Phase 3 myositis and ALKIVIA readouts.
Narrative Update • Jun 02
ARGX: Expanded gMG Label And Myositis Readouts Will Drive Future Repricing Potential
Analysts have nudged their blended price target for argenx higher to about €1,000, reflecting incremental target increases up to €1,291, as they point to upcoming Vyvgart and efgartigimod Phase 3 data and ongoing profitability as key supports for the updated view. Analyst Commentary Bullish analysts are leaning into a constructive view on argenx, pointing to upcoming clinical readouts and recent profitability as key pieces of the story rather than short term trading factors.Recent updates
Narrative Update • Jun 30
ARGX: Myositis Phase 3 Readouts Will Shape Future Earnings Power
Analysts have nudged their average price targets for argenx higher, citing a series of recent target increases into the €1,059 to about €1,291 range and arguing that the market may still underappreciate the potential of Vyvgart in autoimmune myositis and related indications. Analyst Commentary Recent research on argenx centers on how Vyvgart and the broader myositis program could influence the company’s long term value, with several firms updating their models ahead of key Phase 3 readouts.Narrative Update • Jun 16
ARGX: Phase 3 Myositis And ALKIVIA Outcomes Will Test Elevated Stock Expectations
The analyst fair value estimate for argenx has been revised from €614.80 to €644.90 as analysts factor in higher Street price targets and upcoming Phase 3 myositis and ALKIVIA study readouts for Vyvgart and efgartigimod. Analyst Commentary on argenx Recent Street research around argenx highlights a mix of optimism on the clinical pipeline and caution on execution and valuation, giving investors a more balanced picture of risk around Vyvgart and efgartigimod ahead of the Phase 3 myositis and ALKIVIA readouts.Narrative Update • Jun 02
ARGX: Expanded gMG Label And Myositis Readouts Will Drive Future Repricing Potential
Analysts have nudged their blended price target for argenx higher to about €1,000, reflecting incremental target increases up to €1,291, as they point to upcoming Vyvgart and efgartigimod Phase 3 data and ongoing profitability as key supports for the updated view. Analyst Commentary Bullish analysts are leaning into a constructive view on argenx, pointing to upcoming clinical readouts and recent profitability as key pieces of the story rather than short term trading factors.
New Narrative • May 20
High-growth biotech compounding story if VYVGART becomes a multi-indication platform drug
Investment Memo – argenx SE 1. Executive Summary argenx is a commercial-stage biotech in immunology with an active blockbuster (VYVGART) and an advanced pipeline focused on rare autoimmune diseases.Narrative Update • May 14
ARGX: Expanded Neuromuscular Indications Will Support Future Earnings Power
Analysts nudged their blended price target for argenx higher by about €2 to roughly €845, citing a slightly higher fair value estimate, modestly adjusted growth and discount rate assumptions, and support from recent research highlighting Vyvgart momentum and an expanded late stage pipeline. Analyst Commentary Recent research shows a split between analysts trimming targets on fine tuned assumptions and others lifting or reaffirming higher fair value estimates.Narrative Update • Apr 29
ARGX: Graves And gMG Franchise Expansion Will Drive Future Repricing Potential
Analysts have nudged their argenx price targets slightly lower in recent weeks, trimming individual fair values by €30 to €92. They continue to cite ongoing Vyvgart momentum, a broader late stage pipeline and a less demanding valuation as key supports for the updated outlook.Narrative Update • Apr 15
ARGX: Late Stage Neuromuscular Readouts Will Support Future Earnings Power
Analysts have made a modest upward tweak to the fair value estimate for argenx to €842.55, reflecting updated assumptions for Vyvgart momentum, slightly higher revenue growth expectations around 26.7%, a somewhat lower profit margin near 34.7%, and a higher future P/E of about 25.5x following recent price target revisions and ongoing support from research firms despite generally lower headline targets. Analyst Commentary Recent Street research on argenx reflects generally constructive views on Vyvgart execution and the broader pipeline, with some caution around spending plans and the current valuation.Narrative Update • Apr 01
ARGX: Graves And gMG Expansion Will Drive Future Repricing Potential
Analysts have nudged the blended price target for argenx slightly higher to about €991. This reflects updated assumptions that pair more moderate revenue growth with a higher profit margin outlook and a somewhat richer future P/E, supported by recent research citing steady Vyvgart momentum, consistent profitability and a deep late stage pipeline.Narrative Update • Mar 17
ARGX: Late Stage Neuromuscular Pipeline Readouts Will Drive Future Upside
Argenx's updated analyst price target reflects a modest recalibration, with fair value edging from about €845 to €839 as analysts factor in ongoing Vyvgart momentum, a slightly lower future P/E assumption and continued profitability. Analyst Commentary Recent Street research on argenx clusters around two themes: execution on Vyvgart and how much of that outlook is already reflected in the share price.Narrative Update • Mar 03
ARGX: Expanded Neuromuscular Indications Will Drive Long Term Upside Potential
The analyst fair value estimate for argenx edges up from €825.51 to €845.07, as analysts trim long term growth and margin assumptions while still pointing to Vyvgart uptake, late stage pipeline breadth, and ongoing price targets mostly above the current level as key supports for the updated price target range. Analyst Commentary Recent Street research shows a mixed but generally constructive tone around argenx, with price targets adjusted both up and down while ratings largely stay positive.Narrative Update • Feb 17
ARGX: Vyvgart Expansion Into Seronegative gMG Will Support Long Term Upside
Narrative Update Analysts have raised their average price target on argenx by a few euros to €825.51. This reflects updated models that incorporate slightly higher revenue growth assumptions, a modestly higher future P/E multiple and recent target increases from firms citing steady long term confidence in the story.Narrative Update • Feb 03
ARGX: Future Sector Correlation Risk May Undermine Elevated Biotech Thesis
Analysts have lifted their fair value estimate for argenx from US$528.05 to US$614.80, citing updated models that incorporate revised revenue growth, profit margin and future P/E assumptions, in line with a series of recent price target increases from major brokerage firms. Analyst Commentary Recent Street research on argenx has featured a series of higher price targets in both U.S. dollars and euros, reflecting updated models rather than wholesale shifts in underlying views.Narrative Update • Jan 20
ARGX: Graves Disease And gMG Franchise Will Drive Future Repricing
Analysts have raised their fair value estimate for argenx from about $885 to roughly $990.88, citing higher modeled revenue growth assumptions, updated P/E expectations, and a series of price target increases across the Street. Analysts continue to view the company constructively, even as some lists are being rebalanced.Narrative Update • Jan 06
ARGX: Vyvgart Franchise Expansion Will Drive Upside Despite Pipeline Setbacks
Analysts have lifted their fair value estimate for argenx from $797.32 to $820.09. This reflects updated assumptions on discount rate, revenue growth, profit margins and future P/E after recent research that highlighted solid Q3 execution, optimism around Vyvgart's opportunity and some recalibration of upside potential.Narrative Update • Dec 15
ARGX: Future Pipeline Readouts Will Balance Post Rally Expectations And Execution Risks
Analysts have nudged their average price target on argenx modestly higher by about $30 per share. This reflects stronger assumed revenue growth and higher future valuation multiples, even as they temper margin expectations in light of a more selective, probability-weighted view of the Vyvgart and empasiprubart pipelines.Narrative Update • Nov 30
ARGX: Share Momentum Will Balance Pipeline Progress Against Post-Rally Expectations
Argenx's analyst price target has been modestly revised downward by approximately $4 to $766. Analysts are balancing optimism on new clinical data and pipeline expansion with tempered expectations following the recent stock rally.Narrative Update • Nov 16
ARGX: Shares Will Weigh Expanding Indications Against Cooling Market Enthusiasm
Analysts have raised their price target for argenx by over $20 to approximately $770. They cite strong third-quarter performance, broadening growth drivers across Vyvgart indications, and confidence in the company’s expanding pipeline and commercial prospects.Narrative Update • Nov 02
ARGX: Upcoming Phase 3 Readouts and Expanded Access Will Shape Future Outlook
Argenx's analyst price target has increased by over $24 to approximately $749. Analysts cite solid quarterly results, pipeline progress, and expanded commercial opportunities as key drivers for the upward revision.Narrative Update • Sep 25
Aging Trends And Genomics Will Expand Autoimmune Treatment Opportunities
argenx’s consensus price target has been revised upward to €724.38 as analysts raise growth forecasts following strong Phase 3 Vyvgart data and expanding market opportunity, while improved revenue projections and robust pipeline momentum continue to offset valuation concerns. Analyst Commentary Bullish analysts are raising price targets on Argenx following positive topline Phase 3 data for Vyvgart in seronegative myasthenia gravis and successful primary endpoint achievement across patient subtypes, which expands the addressable market.Narrative Update • Aug 29
Aging Trends And Genomics Will Expand Autoimmune Treatment Opportunities
argenx’s price target has been raised to €705.90 as analysts cite strong Vyvgart Phase 3 results, raised U.S. sales expectations, visible pipeline catalysts, and resilient uptake despite recent safety concerns. Analyst Commentary Bullish analysts cite Vyvgart’s positive Phase 3 ADAPT SERON results in seronegative generalized myasthenia gravis (gMG), demonstrating clinical improvement and supporting expansion into new patient subtypes.Narrative Update • Aug 06
Aging Trends And Genomics Will Expand Autoimmune Treatment Opportunities
A sharp decline in argenx’s future P/E ratio, despite slightly lower revenue growth forecasts, has contributed to a notable increase in the consensus analyst price target from €665.23 to €700.31. What's in the News Argenx and Unnatural Products Inc.Analysis Article • Aug 01
What argenx SE's (EBR:ARGX) 25% Share Price Gain Is Not Telling You
argenx SE ( EBR:ARGX ) shares have had a really impressive month, gaining 25% after a shaky period beforehand. Looking...
New Narrative • Apr 27
Prefilled Syringe Launch And Pipeline Trials Will Expand Global Reach
Strong pipeline potential from advanced Phase III and proof-of-concept studies could drive new product approvals and market expansion, boosting revenues.Shareholder Returns
| ARGX | BE Biotechs | BE Market | |
|---|---|---|---|
| 7D | 5.6% | 6.1% | -0.4% |
| 1Y | 79.2% | 44.7% | 25.1% |
Return vs Industry: ARGX exceeded the Belgian Biotechs industry which returned 44.7% over the past year.
Return vs Market: ARGX exceeded the Belgian Market which returned 25.1% over the past year.
Price Volatility
| ARGX volatility | |
|---|---|
| ARGX Average Weekly Movement | 5.1% |
| Biotechs Industry Average Movement | 7.8% |
| Market Average Movement | 3.9% |
| 10% most volatile stocks in BE Market | 7.3% |
| 10% least volatile stocks in BE Market | 2.4% |
Stable Share Price: ARGX's share price has been volatile over the past 3 months compared to the Belgian market.
Volatility Over Time: ARGX's weekly volatility (5%) has been stable over the past year, but is still higher than 75% of Belgian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 1,863 | Karen Massey | argenx.com |
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave’s disease, myositis, Sjögren’s disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy.
argenx SE Fundamentals Summary
| ARGX fundamental statistics | |
|---|---|
| Market cap | €49.35b |
| Earnings (TTM) | €1.30b |
| Revenue (TTM) | €4.16b |
39.3x
P/E Ratio12.3x
P/S RatioIs ARGX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ARGX income statement (TTM) | |
|---|---|
| Revenue | US$4.74b |
| Cost of Revenue | US$1.99b |
| Gross Profit | US$2.76b |
| Other Expenses | US$1.27b |
| Earnings | US$1.49b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Jul 23, 2026
| Earnings per share (EPS) | 23.94 |
| Gross Margin | 58.11% |
| Net Profit Margin | 31.40% |
| Debt/Equity Ratio | 0.6% |
How did ARGX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/02 21:28 |
| End of Day Share Price | 2026/07/02 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
argenx SE is covered by 52 analysts. 31 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Baird |
| Colleen Kusy | Baird |
| Joel Beatty | Baird |